Saturday 17 October 2026
Export BEAM’s income statement to Excel — free account
Beam Therapeutics Inc.
BEAM Healthcare Biotechnology
Beam Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $139.7 million, up 120.0% from fiscal 2024. In the quarter to June 2026, revenue fell 94.2%, EPS fell 18.0% and free cash flow grew 13.9%, each against the same quarter a year earlier.
23.47
1.26
−5.10%
Follow BEAM
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
3 | 4 | 3 | 3 |
| (47.07%) | (8.11%) | (5.77%) | (8.18%) | ||
| (33.32%) | (6.19%) | (4.48%) | (6.23%) | ||
ROIC |
0.00% | 0.00% | (438.41%) | (1,599.30%) | |
Return on Tangible Assets |
(40.37%) | (6.27%) | (5.10%) | (7.24%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(3.44) | (3.64) | (3.72) | (3.57) | |
Free Cash Flow |
(352.36) | (360.05) | (383.84) | (372.77) | |
Capital Expenditures |
(14.18) | (14.95) | (14.11) | (13.39) | |
| Other line items | |||||
Cash ROIC |
(17.26%) | (14.50%) | (15.50%) | (16.06%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
739.28% | 293.12% | 253.23% | 261.91% | |
Selling, General and Administrative Expense of Revenue |
197.84% | 81.45% | 73.35% | 80.36% | |
Share Based Compensation of Revenue |
186.74% | 67.44% | 52.80% | 52.24% | |
Operating CF/Net income |
0.82 | 4.31 | 5.60 | 4.15 | |
Depreciation/Fixed assets |
0.04 | 0.06 | 0.07 | 0.10 | |
Capex/Depreciation |
(3.00) | (2.36) | (1.87) | (1.41) | |
Revenue per Share |
0.54 | 1.41 | 1.59 | 1.50 | |
Operating CF per Share |
(3.30) | (3.49) | (3.58) | (3.44) | |
Capex per Share |
(0.14) | (0.15) | (0.14) | (0.13) | |
Capex to Sales |
0.25 | 0.11 | 0.09 | 0.09 |
Columns are period end dates